Compare O'Reilly Automotive Inc. Common Stock (ORLY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
O'Reilly Automotive Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? O'Reilly Automotive Inc. Common Stock trades at $87.78 (market cap $69.59B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: O'Reilly Automotive Inc. Common Stock is far larger — about 9.3× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, O'Reilly Automotive Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| ORLY | SYRE | |
|---|---|---|
Market Cap | $69.59B | $7.52B |
Volume | 3,367,517 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $102.12 | $108.92 |
52-Week Low | $82.73 | $22.18 |
Enterprise Value | $78.92B | $6.52B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
O'Reilly Automotive (ORLY) trades at $86.03, down 0.72% on the day, amid a mixed technical picture with a bullish overall signal but bearish moving averages. The company reported strong fundamentals with 2025 revenue of $17.78 billion and net income of $2.54 billion, maintaining a robust net income margin of 14.27%. Recent news highlights its defensive positioning in the auto parts market and upcoming Q3 2026 earnings release on October 28, 2026.
The outlook remains positive with a consensus price target of $106.09, implying significant upside. Key opportunities include resilient demand from an aging vehicle fleet and expansion plans in Mexico. Risks involve competitive pressures and potential macroeconomic headwinds affecting consumer spending on auto repairs. Analyst sentiment is strongly bullish with 59.57% buy ratings.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About O'Reilly Automotive Inc. Common Stock
O'Reilly Automotive sells automotive aftermarket parts, tools, supplies, equipment, and accessories. It serves both professional service providers and do-it-yourself customers through its store network.
Read more on ORLY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
